However, the combination of Apo2L/TRAIL and gemcitabine can enhance the anti-tumor effect against Apo2L/TRAIL sensitive tumors and, importantly, can overcome resistance to either single agent, and result in suppression of resistant tumors. The gene discussed is TNFSF10; the disease is neoplasm.